A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 03 May 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 09 Apr 2019 Status changed to discontinued.
- 06 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 24 Sep 2015 Addition of toxicity study of the drug in primary endpoints and change of trial focus fro TU to TU & AR.